Guinea

Description of efforts by the big drug companies to develop an Ebloa vaccine
THE NEW YORKER    By Vauhine Vara                        Nov. 25, 2014

"...why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson—three of the world’s biggest drug manufacturers? For years, pharmaceutical companies didn’t invest much in vaccines, partly because they were so costly and complicated to produce: they’re often made out of live bacteria, which are notoriously difficult to work with. But, over the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic-drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription-drug market. The World Health Organization estimates, based on various sources, that global vaccine sales rose from five billion dollars in 2000 to twenty-four billion dollars last year...."

Read complete article
http://www.newyorker.com/business/currency/race-ebola-vaccine

TIME MAGAZINE By Alexandra Sifferlin                          Nov. 25, 2014
 By  Alexandra Sifferlin                       

Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.

The University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.

Manufacturers Strain to Meet Demand Amid Rising Anxiety

WALL STREET JOURNAL                                                                                                       Nov. 25, 2014
 By Drew Hinshaw in Accra, Ghana, and Jacob Bunge in Chicago

Protective suits were running low in Sierra Leone this month, when a Christian charity decided to ship some over. The charity turned to American medical-wear suppliers, which came back with bad news: The suits needed to treat Ebola are running low in America, too.

A worker wearing Personal Protective Equipment has his name written on his suit before leaving an Ebola treatment center in Guinea last week. Agence France-Presse/Getty Images

“There’s been some sleepless nights,” said Jennifer Mounsey, director of corporate engagement for World Vision, the Christian humanitarian group based in Monrovia, Calif. “We’re all sweating bullets.”

November 25, 2014 - by Kelly McEvers - npr.org

The Ebola outbreak started in rural areas, but by June it had reached Liberia's capital, Monrovia.

By August, the number of people contracting the Ebola virus in the country was doubling every week. The Liberian government and aid workers begged for help.

Enter the U.S. military, who along with other U.S. agencies had a clear plan in mid-September to build more Ebola treatment units, or ETUs. At least one would be built in the major town of each of Liberia's 15 counties. That way, sick patients in those counties wouldn't bring more Ebola to the capital.

But it's taken a long time to build these ETUs; most won't be done until the end of the year. And now the spread of Ebola changing — clusters are popping up in remote rural areas. So building a huge treatment center in each county's main town may no longer make sense.